About Event
Pharma & Biotech’s First & Only Forum Dedicated to Claudin-Targeted
Therapeutic Development
With big pharma investing in claudin-targeted pipelines, over 110 active Claudin-targeted drugs, and a wealth of powerful modalities including bispecifics, ADCs, and CAR-TCRs heading to the clinic, the race is heating up to bring more efficacious and safer claudin treatments to patients in gastrointestinal, pancreatic, ovarian cancer and beyond.
Uniting over 50 claudin drug developers from top biopharma companies, the Claudin-Targeted Therapies Summit offers unparalleled insights into optimizing target selectivity, exploring claudin expression across diverse cancer indications, and showcasing development of efficacious modalities to advance the next wave of claudin-targeted therapies.
Join Your Peers to:
1
Join Your Peers to uncover Claudin Insights from Zolbertuximab & Beyond
Gain in-depth knowledge of the latest clinical developments in Claudin-targeted therapies, including leveraging the perspectives from the approval of Zolbertuximab with Kohei Shitara and Astellas to guide the future development of your Claudin-targeted drugs
2
Advance Strategies for Claudin Therapy Toxicity Mitigation
Learn comprehensive strategies to manage and mitigate the toxicities associated with Claudin-targeted therapies. Through expert-led workshops and sessions from Innovent Biologics and Astellas Pharma, explore real-world examples and innovative approaches to ensure patient safety and treatment efficacy.
3
Understand the Synergistic Potential of Claudin Combinations
Explore the synergistic potential of combining Claudin-targeted therapies with other anti-cancer treatments such as immunotherapies to enhance therapeutic outcomes through combination strategies with like Transcenta and AstraZeneca
4
Improve Translation of Claudin Therapies from Bench to Bedside
Gain practical knowledge on how to successfully translate preclinical findings into clinical success. Enjoy case studies and best practices led by I-mab Biopharma and ADC Therapeutics to overcome challenges in the clinical development of Claudin-targeted therapies, focusing on target specificity and optimizing therapeutic windows
5
Discover Future Trends & Innovations in Claudin Therapies
Stay ahead of the curve by learning about the latest trends and innovations in Claudin-targeted therapy development. From emerging technologies and therapeutic approaches, enjoy insights into next-generation antibodies and cell therapies from Bolt Biotherapeutics and Triumvira Immunologics
Who Will You Meet?
Join the Claudin-Targeted Therapies Summit to engage with a highly specialized audience comprising preclinical, translational, PKPD, and clinical development experts from leading biopharma companies including AstraZeneca, Astellas Pharma, Xencor, Integral Molecular and Innovent Biologics.
With a speaker faculty headlined by C-level biopharma decision makers and director-level pharma leaders, this is the must-attend summit for anyone working on claudin targeted therapies, providing a unique learning and networking opportunity with industry leaders driving the next wave of claudin-targeted cancer treatments.
Hear From Past Attendees of the Therapeutics & Indications Event Series:
“Good content and I learned many new things that are relevant to my work.”
“I really enjoyed how small and intimate, yet very well represented the event was. It was the perfect number of people that enabled the ability to easily connect and speak with whoever was present.”
“I really enjoyed how small and intimate, yet very well represented the event was. It was the perfect number of people that enabled the ability to easily connect and speak with whoever was present.”
“It was thrilling to hear so much cutting-edge science. The speakers were extremely knowledgeable about their subjects”
